Overview

Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma

Status:
Recruiting

Trial end date:
2023-01-06

Target enrollment:

Participant gender:

Summary

This phase I trial studies best dose and how well copanlisib when given together with nivolumab works in treating participants with Richter's transformation or transformed indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab may work better in treating participants with Richter's transformation or transformed non-Hodgkin's lymphoma.

Phase:

Phase 1

Details

Lead Sponsor:

City of Hope Medical Center
OHSU Knight Cancer Institute

Collaborators:

National Cancer Institute (NCI)
Oregon Health and Science University

Treatments:

Nivolumab